|Bid||0.790 x 800|
|Ask||0.820 x 1100|
|Day's Range||0.780 - 0.830|
|52 Week Range||0.650 - 8.400|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City. vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. This release contains forward-looking statements, which involve risks and uncertainties.
A closer look at data from two clinical trials reveals what company executives believe is potential for vTv Therapeutics's investigational Alzheimer's drug to get FDA approval for further testing.
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -16.00% and 0.69%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 31 cents. Losses, adjusted for non-recurring costs, came to 29 cents per share. The results fell short of Wall Street ...
vTv Therapeutics Inc. today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.
For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.
Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Fla., June 22–26, 2018. “As the first company to evaluate a Glucokinase Activator in people with type 1 diabetes, we are very excited to be sharing this clinical data at the American Diabetes Association’s 78th Scientific Sessions,” said Carmen Valcarce, Ph.D., executive vice president, chief scientific officer, vTv Therapeutics.
vTv Therapeutics Inc. (VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.
High Point-based vTv Therapeutics has inked an agreement with a Chinese company for rights to develop and commercialize a drug candidate aimed at respiratory and other inflammatory diseases. China’s Newsoara Biopharma Co. Ltd. has acquired rights for HPP737, a selective phosphodiesterase type 4 (PDE4) inhibitor, that has shown therapeutic activity in several animal models for inflammation. It will be able to commercialize the product in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea.
vTv Therapeutics Inc. (VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea. Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara will develop HPP737 in the covered territories for respiratory and other inflammatory diseases.
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
vTv Therapeutics Inc. today reported financial and operational results for the first quarter that ended March 31, 2018.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...
vTv Therapeutics Inc. (VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease, despite not meeting co-primary endpoints, identified a subpopulation that showed statistically significant benefit (unadjusted for multiple, post hoc comparisons) from azeliragon relative to placebo on ADAS-cog. Based on the subpopulation data analyses from the Part A study and the prior azeliragon trials, the company will submit a revised Statistical Analysis Plan (SAP) to the Food and Drug Administration for the Part B Study that pre-specifies a target population for the primary study analysis and expects to report Part B topline efficacy results based on 12 month data in June 2018.
The executive is leaving about three weeks after the clinical stage pharmaceutical company announced disappointing trial results for one of its key drug prospects that was aimed at Alzheimer's.
Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.
The prospect of vTv Therapeutics moving its office was raised after it was revealed Cambrex Corp. bought the building. The company is also ending clinical trials for an Alzheimer's drug it has been developing.
It's the first day the stock hit above $1 since vTv Therapeutics reported disappointing results from the Phase 3 study of its drug azeliragon.
Cambrex has taken steps toward another expansion by buying up two buildings for $10.2 million.
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.